Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder

Psychiatry Investigation

Volumn 10, Issue 3, 2013, Pages 294-299

  Kim, Jae Won ^a   Kim, Yong Ku ^a   Hwang, Jung A ^a   Yoon, Ho Kyoung ^a   Ko, Young Hoon ^a   Han, Changsu ^a   Lee, Heon Jeong ^a   Ham, Byung Joo ^a   Lee, Hong Seock ^b  

^a Korea University College of Medicine   (South Korea)

^b Hallym University Medical Center   (South Korea)

Author keywords

Cytokine; IL 17; IL 23; Immune; Major depressive disorder; Th17 cell

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; INTERLEUKIN 17; INTERLEUKIN 23; MIRTAZAPINE; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; OPTICAL DENSITY;

EID: 84885821844     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2013.10.3.294     Document Type: Article

References (38)

1. Dubas-Slemp H, Marmurowska-Michalowska H, Szuster-Ciesielska A, Kaminska T, Kandefer-Szerszen M. The role of cytokines in depression. Psychiatr Pol 2003;37:787-798.
2. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-217.
3. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374-383.
4. Munoz-Fernandez MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307-340.
5. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001;54:329-338.
6. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1044-1053.
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446-457.
8. Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005;88:167-173.
9. Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011;43: 503-511.
10. Vojdani A, Lambert J. The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I. Evid Based Complement Alternat Med 2011;2011:927294.
11. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-124.
12. Shen W, Durum SK. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res 2010;35:940-946.
13. Maeda S, Hayami Y, Naniwa T, Ueda R. The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. Int J Rheumatol 2012;2012:539683.
14. Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res 2010;30:751-757.
15. Liu Y, Zhu H, Su Z, Sun C, Yin J, Yuan H, et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta/Erk1/2/NF-kappaB-dependent signaling pathway. Int Immunol 2012;24:605-612.
16. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Modern Rheumatol 2009;19:657-662.
17. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008;14:337-342.
18. Misery L. Depression and psoriasis. Ann Dermatol Venereol 2012;139 (Suppl 2):S53-S57.
19. Feher J, Kovacs I, Balacco Gabrieli C. [Role of gastrointestinal inflammations in the development and treatment of depression]. Orv Hetil 2011;152:1477-1485.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Press; 2000.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis 2012; 15:183-187.
23. Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z, et al. Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells. Psychiatry Res 2011;188:224-230.
24. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206.
25. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995;762:474-476.
26. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995;41:534-538.
27. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326-331.
28. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6: 1298-1304.
29. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
30. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361.
31. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011;16:751-762.
32. Brambilla F, Monteleone P, Maj M. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J Affect Disord 2004;78:273-277.
33. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord 2004;79:285-289.
34. Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F, et al. Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 2007;41:152-159.
35. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a metaanalysis. Neuropsychopharmacology 2011;36:2452-2459.
36. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445-450.
37. Haastrup E, Knorr U, Erikstrup C, Kessing LV, Ullum H. No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. J Neuroimmunol 2012; 243:69-72.
38. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407-418.